| First Author | Khan MW | Year | 2022 |
| Journal | Cell Death Dis | Volume | 13 |
| Issue | 7 | Pages | 660 |
| PubMed ID | 35902556 | Mgi Jnum | J:327071 |
| Mgi Id | MGI:7327676 | Doi | 10.1038/s41419-022-04999-z |
| Citation | Khan MW, et al. (2022) The hexokinase "HKDC1" interaction with the mitochondria is essential for liver cancer progression. Cell Death Dis 13(7):660 |
| abstractText | Liver cancer (LC) is the fourth leading cause of death from cancer malignancies. Recently, a putative fifth hexokinase, hexokinase domain containing 1 (HKDC1), was shown to have significant overexpression in LC compared to healthy liver tissue. Using a combination of in vitro and in vivo tools, we examined the role of HKDC1 in LC development and progression. Importantly, HKDC1 ablation stops LC development and progression via its action at the mitochondria by promoting metabolic reprogramming and a shift of glucose flux away from the TCA cycle. HKDC1 ablation leads to mitochondrial dysfunction resulting in less cellular energy, which cannot be compensated by enhanced glucose uptake. Moreover, we show that the interaction of HKDC1 with the mitochondria is essential for its role in LC progression, and without this interaction, mitochondrial dysfunction occurs. As HKDC1 is highly expressed in LC cells, but only to a minimal degree in hepatocytes under normal conditions, targeting HKDC1, specifically its interaction with the mitochondria, may represent a highly selective approach to target cancer cells in LC. |
